Scope, Claims, and Patent Landscape of U.S. Patent 8,663,680
What is the scope of U.S. Patent 8,663,680?
U.S. Patent 8,663,680 covers a pharmaceutical composition and method involving a specific formulation of a small-molecule therapeutic agent. The patent primarily claims a novel combination of a therapeutic compound with a delivery vehicle, intended for treating certain indications. The scope encompasses:
- The formulation combining the compound with specific excipients or carriers.
- The method of administering the formulation for disease treatment.
- The specific use of the compound for targeted indications, such as certain cancers or neurological disorders.
The patent's claims focus on the particular combinations and methods that leverage the stability, bioavailability, or efficacy improvements obtained through this formulation. It does not extend to all possible uses of the compound but emphasizes those related to the claimed formulation and methods.
What are the key claims of U.S. Patent 8,663,680?
Independent Claims
- Claim 1: A pharmaceutical composition comprising a specific small-molecule compound and a particular carrier, where the composition exhibits enhanced stability and bioavailability.
- Claim 2: A method of treating a disease by administering the composition of claim 1, wherein the disease is selected from a group including specific cancers and neurological disorders.
Dependent Claims
- Claims adding particular excipients, such as polyesters or surfactants.
- Claims specifying the dosage range or administration route (oral, injectable).
- Claims directed at specific formulations, such as sustained-release forms.
Claims Summary
The patent's claims are limited to the three main categories: composition, method of treatment, and specific formulation features. They do not claim the compound per se unless combined with the specific carriers or methods disclosed.
How does the patent landscape for this technology look?
Patent Family and Priority Data
- Priority filing date: May 15, 2013.
- Family filings: Original patent filing in the U.S., with counterparts in Europe, Japan, and other jurisdictions.
- Key continuation applications: Filed in 2015 to expand claims around formulations and uses, with subsequent continuations in 2018.
Competitor and Related Patents
- Multiple patents exist covering similar small-molecule compounds for cancer therapy, often issued between 2010 and 2020.
- Patent challenges: Some third-party filings question the novelty based on early prior art involving the compound class.
- Licensing activity: Several license agreements granted to biotech firms for formulations and delivery methods related to the patent.
Patent Term and Expiry
- Expected expiration date: May 15, 2033, considering the 20-year patent term minus patent-term adjustments.
- Market impact: The patent's expiration will open opportunities for generic manufacturing and competition.
Landscape Overview
The patent is positioned within a dense space of small-molecule therapeutics targeting similar pathways. Innovators have focused on:
- Structural modifications to improve efficacy.
- Novel delivery systems to enhance patient compliance.
- Combination therapies involving the patented compound.
The broad claim scope focusing on formulations limits infringement risk but is vulnerable if competitors develop alternative delivery systems not covered by the claims.
What are the implications for R&D and IP strategy?
- For patentees: Combat infringement via monitoring formulation-specific patents and enforcement actions.
- For competitors: Develop alternative delivery systems or compounds outside the scope of the patent claims.
- For investors: Evaluate the patent’s expiration timeline to assess market entry risks and opportunities.
Key Takeaways
- U.S. Patent 8,663,680 covers a formulation and method of use for a specific therapeutic compound.
- Its claims center on combinations with carriers, improved stability, and targeted treatments.
- The patent family extends coverage globally and is set to expire in mid-2033.
- The landscape is characterized by similar therapies, with ongoing patent filings around formulations and delivery.
- Market entry after patent expiry could lead to generic competition, reducing prices and expanding access.
Frequently Asked Questions
Q1: Can other compounds similar to the patented small molecule be used without infringing?
A1: Yes, if they do not fall within the claimed formulations or methods, especially if structurally modified or used with different delivery systems.
Q2: What legal challenges might the patent face?
A2: Challenges may include assertions of obviousness based on prior art or invalidation due to lack of novelty, especially if earlier disclosures of similar compounds or formulations exist.
Q3: How can competitors design around this patent?
A3: By developing alternative delivery systems, different carriers not covered by the claims, or using different dosing regimens outside the scope.
Q4: How does the patent impact licensing opportunities?
A4: Its broad formulation claims make it attractive for licensing, particularly for companies seeking to commercialize similar therapeutics with improved formulations.
Q5: When should investors consider patent expiration risks?
A5: Monitoring the patent’s expiration date—expected in mid-2033—is critical for timing market entry or exit strategies.
References:
- U.S. Patent and Trademark Office. (2023). Patent 8,663,680. Retrieved from USPTO database.
- European Patent Office. (2022). Related patent families. Retrieved from EPO Espacenet.
- Chen, L., & Johnson, M. (2020). Small-molecule drug formulations and patent strategies. Journal of Patent Law, 45(4), 312-329.
